Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up

Diabetes Technology and Therapeutics

Volumn 12, Issue 5, 2010, Pages 387-391

  Klupa, Tomasz ^a,b   Skupien, Jan ^a,b   Mirkiewicz Sieradzka, Barbara ^a,b   Gach, Agnieszka ^c   Noczynska, Anna ^d   Zubkiewicz Kucharska, Agnieszka ^d   Szalecki, Mieczyslaw ^e   Kozek, Elzbieta ^a,b   Nazim, Joanna ^a   Mlynarski, Wojciech ^c   Malecki, MacIej T ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e Provincial Hospital in Kielce   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; SULFONYLUREA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLYCEMIC CONTROL; HUMAN; LONG TERM CARE; MALE; NEWBORN DISEASE; PERMANENT NEONATAL DIABETES MELLITUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TOOTH DISCOLORATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 77951121887     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0165     Document Type: Article

References (22)

1. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATPsensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849.
2. Ashcroft FM: The Walter B. Cannon Physiology in Perspective Lecture, 2007: ATP-sensitive K+ channels and disease: from molecule to malady. Am J Physiol Endocrinol Metab 2007;293:E880-E889.
3. Koster JC, Remedi MS, Dao C, Nichols CG: ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy. Diabetes 2005;54:2645-2654.
4. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Aschcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT; Neonatal Diabetes International Collaborative Group: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477.
5. Klupa T, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki M: The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005;48:1029-1031.
6. Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I: Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 2007; 92:1276-1282.
7. Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F; Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology: Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Diabetologia 2006;49:2210-2213.
8. Groop L: Drug treatment of non-insulin-dependent diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of Diabetes, 2nd ed. Oxford, UK: Blackwell Science, 1997:38.1-38.17.
9. Klupa T, Skupien J, Mirkiewicz-Sieradzka B, Gach A, Noczynska A, Szalecki M, Kozek E, Sieradzki J, Młynarski W, Malecki MT: Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea. Diabet Med 2009;26:663-664.
10. Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM: Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by mutation in KCNJ11. Nat Clin Pract Neurol 2007;3:640-645.
11. Begum-Hasan J, Polychronakos C, Brill H: Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy-a three-year follow-up. J Pediatr Endocrinol Metab 2008;21:895-903.
12. Holl RW, Lang GE, Grabert M, Heinze E, Lang GK, Debatin KM: Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. J Pediatr 1998; 132:790-794.
13. Donaghue KC, Fung AT, Hing S, Fairchild J, King J, Chan A, Howard NJ, Silink M: The effect of prepubertal diabetes duration on diabetes. Microvascular complications in early and late adolescence. Diabetes Care 1997;20:77-80.
14. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102:647-661.
15. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 1988;260:37-41.
16. Ihnat MA, Thorpa JE, Ceriello A: Hypothesis: the ''metabolic memory,'' the new challenge of diabetes. Diabet Med 2007; 24:582-586.
17. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S: Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008;14:962-968.
18. Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC, Bruining GJ, Hattersley AT, Hadders-Algra M: Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008;25:277-281.
19. Cooper EC, Pan Z: Putting an end to DEND: a severe neonatal-onset epilepsy is treatable if recognized early. Neurology 2007;69:1310-1311.
20. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F: The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008;93:1054-1061.
21. Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J: Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating mutations: evidence for improvement in insulin sensitivity. Diabetes Care 2007;30: 147-149.
22. Kumaraguru J, Flanagan SE, Greeley SA, Nuboer R, Støy J, Philipson LH, Hattersley AT, Rubio-Cabezas O: Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect. Diabetes Care 2009;32:1428-1430.